Dataset from PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED EAST ASIAN PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS

This is a Phase III, Randomized, Open-label, Efficacy and Safety Study of Crizotinib single
agent versus Chemotherapy Regimens (Pemetrexed/Cisplatin or Pemetrexed/Carboplatin) in
First-Line ALK (Anaplastic Lymphoma Kinase) Positive East Asian Non-Small Cell Lung Cancer
Patients. The objective of the study is to demonstrate that Crizotinib is superior to
first-line chemotherapy pemetrexed/cisplatin or pemetrexed/carboplatin in prolonging
Progression Free Survival (PFS) in East Asian patients with advanced Non-Squamous NSCLC whose
tumors harbor a translocation or inversion event involving the ALK (Anaplastic Lymphoma
Kinase) gene locus.